Skip to content
    Guidelines & Consensus

    ACS Peachtree Consensus Issues Guidelines for Multicancer Early Detection Trials

    Etzioni et alCancer

    To address the emerging shift in multicancer early detection (MCED) trial methodology from traditional cancer mortality to late-stage incidence end points, an American Cancer Society workshop of 15 academic screening evaluation experts developed the Peachtree Consensus. These consensus recommendations establish standardized principles to safeguard trial validity, interpretability, and clinical applicability.\n\nThe consensus panel highlights that the definition of late-stage cancer fundamentally dictates study design, analytical interpretation, and clinical conclusions. Investigators are advised to adopt cancer-type-specific definitions of late stage and ensure comparable staging intensity across both intervention and control arms to avoid detection bias. Additionally, the screening duration and post-screening follow-up windows must be tailored to the preclinical early- and late-stage durations of the targeted cancers.\n\nFor analysis and reporting, the panel advises presenting both aggregate and cancer-specific results as sample size permits, detailing both absolute and relative risk reductions. Because late-stage incidence is an intermediate end point, studies should calculate predicted mortality reductions and report all supporting inputs and assumptions. When a trial demonstrates a statistically significant reduction in late-stage incidence indicative of clinical utility, the authors support launching consortium and demonstration studies while maintaining active tracking of mortality end points to establish evidence-based screening guidelines.

    Key Takeaways

    • The American Cancer Society Peachtree Consensus recommends that multicancer early detection trials utilizing late-stage incidence end points implement cancer-type-specific definitions, maintain equivalent staging intensity between study arms, report predicted mortality reductions with explicit modeling assumptions, and continue tracking trial mortality outcomes.